Ambit Biosciences Corporation Stockholders Encouraged to Contact Securities Law Firm about Takeover

NEW YORK, Oct. 1, 2014 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating the board of Ambit Biosciences Corporation (NASDAQ: AMBI) in connection with a buyout for only $15 per share. Concerned AMBI investors are encouraged to contact attorney Hamilton Lindley by clicking here.

Because at least one analyst has a $17 per share target price, the deal appears to undervalue AMBI. The securities law firm's proposed shareholder action seeks to ensure that shareholders receive the highest price reasonably available and disclosure of all important information to shareholders of Ambit Biosciences. 

Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. AMBI stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] with questions, toll free at (844) 702-2990 or visit http://www.dunnamlaw.com/AMBI.

SOURCE Dunnam & Dunnam